Calidi reports Q1 net loss $5.0M; CEO transition to Eric Poma; FDA clears CLD-201 IND

Calidi Biotherapeutics, Inc.

CEO transition: Eric Poma appointed CEO; 30+ yrs biopharma; raised >$250M at Molecular Templates.
FDA cleared IND for CLD-201 (allogeneic stem cell therapy) for solid tumors; CIRM non-dilutive funding.
Selected IL-15 superagonist as first payload for Redtail platform; IND filing expected H2 2026.
Q1 net loss $5.0M ($0.18/share) vs $7.2M ($2.03/share) in Q1 2024; R&D $2.4M, G&A $2.6M.
Cash $10.6M at March 31, 2025, up from $9.6M at Dec 31, 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.